Anatara Lifesciences Ltd (ASX: ANR) has provided the summary of the preclinical studies for its Gastrointestinal ReProgramming (GaRP) dietary supplement as it targets commencement of a human clinical trial in 2Q 2020.
Successful preclinical program has provided strong scientific proof that GaRP dietary supplement of Anatara may be the breakthrough product that is urgently required by the patients who suffers from chronic bowel conditions.
In summary, GaRP:
- Addressed the dysbiosis of the microbiome
- Reduced gut inflammation
- Promoted mucosal healing
GaRP is capable of providing:
- An adjuvant effect in lessening inflammation with the co-administration of disease-modifying medications.
- Dose decrease of disease-modifying medications known to have harmful side-effect.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.